Endocrine Testing Market Size, Share & Trends Report

Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (TSH, hCG Hormone), By End-use (Hospitals, Commercial Laboratories), By Technology (Immunoassay, Clinical Chemistry), And Segment Forecasts, 2024 - 2030

Report ID: 978-1-68038-862-6
Number of Report Pages: 180
Format: PDF

Historical Range: 2018 - 2023
Forecast Period: 2024 - 2030
Industry: Healthcare

Market Segmentation

Endocrine Testing Test Type Outlook (Revenue, USD Million, 2018 - 2030)
- Estradiol (E2) Test
- Follicle Stimulating Hormone (FSH) Test
- Human Chorionic Gonadotropin (hCG) Hormone Test
- Luteinizing Hormone (LH) Test
- Dehydroepiandrosterone Sulfate (DHEAS) Test
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone (TSH) Test
- Prolactin Test
- Cortisol Test
- Insulin Test
- Others
Endocrine Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)
- Tandem Mass Spectrometry
- Immunoassay
- Monoclonal & Polyclonal Antibody Technologies
- Sensor Technology
- Clinical Chemistry
- Others
Endocrine Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Commercial Laboratories
- Ambulatory Care Centers
- Others
Endocrine Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Test Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Estradiol (E2) Test
    - Follicle Stimulating Hormone (FSH) Test
    - Human Chorionic Gonadotropin (hCG) Hormone Test
    - Luteinizing Hormone (LH) Test
    - Dehydroepiandrosterone Sulfate (DHEAS) Test
    - Progesterone Test
    - Testosterone Test
    - Thyroid Stimulating Hormone (TSH) Test
    - Prolactin Test
    - Cortisol Test
    - Insulin Test
    - Others
  - North America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Immunoassay
    - Monoclonal & Polyclonal Antibody Technologies
    - Sensor Technology
    - Clinical Chemistry
    - Others
  - North America End-use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Commercial Laboratories
    - Ambulatory Care Centers
    - Others
  - U.S.
    - U.S. Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - U.S. Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - U.S. End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Canada
    - Canada Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Canada Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Canada End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
- Europe
  - Europe Test Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Estradiol (E2) Test
    - Follicle Stimulating Hormone (FSH) Test
    - Human Chorionic Gonadotropin (hCG) Hormone Test
    - Luteinizing Hormone (LH) Test
    - Dehydroepiandrosterone Sulfate (DHEAS) Test
    - Progesterone Test
    - Testosterone Test
    - Thyroid Stimulating Hormone (TSH) Test
    - Prolactin Test
    - Cortisol Test
    - Insulin Test
    - Others
  - Europe Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Immunoassay
    - Monoclonal & Polyclonal Antibody Technologies
    - Sensor Technology
    - Clinical Chemistry
    - Others
  - Europe End-use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Commercial Laboratories
    - Ambulatory Care Centers
    - Others
  - U.K.
    - U.K. Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - U.K. Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - U.K. End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Germany
    - Germany Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Germany Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Germany End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - France
    - France Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - France Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - France End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Italy
    - Italy Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Italy Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Italy End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Spain
    - Spain Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Spain Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Spain End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Denmark
    - Denmark Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Denmark Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Denmark End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Sweden
    - Sweden Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Sweden Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Sweden End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Norway
    - Norway Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Norway Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Norway End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
- Asia Pacific
  - Asia Pacific Test Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Estradiol (E2) Test
    - Follicle Stimulating Hormone (FSH) Test
    - Human Chorionic Gonadotropin (hCG) Hormone Test
    - Luteinizing Hormone (LH) Test
    - Dehydroepiandrosterone Sulfate (DHEAS) Test
    - Progesterone Test
    - Testosterone Test
    - Thyroid Stimulating Hormone (TSH) Test
    - Prolactin Test
    - Cortisol Test
    - Insulin Test
    - Others
  - Asia Pacific Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Immunoassay
    - Monoclonal & Polyclonal Antibody Technologies
    - Sensor Technology
    - Clinical Chemistry
    - Others
  - Asia Pacific End-use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Commercial Laboratories
    - Ambulatory Care Centers
    - Others
  - China
    - China Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - China Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - China End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Japan
    - Japan Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Japan Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Japan End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - India
    - India Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - India Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - India End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Australia
    - Australia Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Australia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Australia End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Thailand
    - Thailand Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Thailand Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Thailand End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - South Korea
    - South Korea Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - South Korea Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - South Korea End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
- Latin America
  - Latin America Test Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Estradiol (E2) Test
    - Follicle Stimulating Hormone (FSH) Test
    - Human Chorionic Gonadotropin (hCG) Hormone Test
    - Luteinizing Hormone (LH) Test
    - Dehydroepiandrosterone Sulfate (DHEAS) Test
    - Progesterone Test
    - Testosterone Test
    - Thyroid Stimulating Hormone (TSH) Test
    - Prolactin Test
    - Cortisol Test
    - Insulin Test
    - Others
  - Latin America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Immunoassay
    - Monoclonal & Polyclonal Antibody Technologies
    - Sensor Technology
    - Clinical Chemistry
    - Others
  - Latin America End-use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Commercial Laboratories
    - Ambulatory Care Centers
    - Others
  - Brazil
    - Brazil Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Brazil Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Brazil End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Mexico
    - Mexico Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Mexico Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Mexico End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Argentina
    - Argentina Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Argentina Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Argentina End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
- Middle East & Africa
  - Middle East & Africa Test Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Estradiol (E2) Test
    - Follicle Stimulating Hormone (FSH) Test
    - Human Chorionic Gonadotropin (hCG) Hormone Test
    - Luteinizing Hormone (LH) Test
    - Dehydroepiandrosterone Sulfate (DHEAS) Test
    - Progesterone Test
    - Testosterone Test
    - Thyroid Stimulating Hormone (TSH) Test
    - Prolactin Test
    - Cortisol Test
    - Insulin Test
    - Others
  - Middle East & Africa Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Immunoassay
    - Monoclonal & Polyclonal Antibody Technologies
    - Sensor Technology
    - Clinical Chemistry
    - Others
  - Middle East & Africa End-use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Commercial Laboratories
    - Ambulatory Care Centers
    - Others
  - South Africa
    - South Africa Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - South Africa Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - South Africa End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Saudi Arabia
    - Saudi Arabia Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Saudi Arabia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Saudi Arabia End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - UAE
    - UAE Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - UAE Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - UAE End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others
  - Kuwait
    - Kuwait Test Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Estradiol (E2) Test
      - Follicle Stimulating Hormone (FSH) Test
      - Human Chorionic Gonadotropin (hCG) Hormone Test
      - Luteinizing Hormone (LH) Test
      - Dehydroepiandrosterone Sulfate (DHEAS) Test
      - Progesterone Test
      - Testosterone Test
      - Thyroid Stimulating Hormone (TSH) Test
      - Prolactin Test
      - Cortisol Test
      - Insulin Test
      - Others
    - Kuwait Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Immunoassay
      - Monoclonal & Polyclonal Antibody Technologies
      - Sensor Technology
      - Clinical Chemistry
      - Others
    - Kuwait End-use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Commercial Laboratories
      - Ambulatory Care Centers
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.